Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metagenomic sequencing of mpox virus clade Ib lesions identifies possible bacterial and viral co-infections in hospitalized patients in eastern DRC

  • Schuele, Leonard
  • Masirika, Leandre Murhula
  • Boter, Marjan
  • Ndishimye, Pacifique
  • Udahemuka, Jean Claude
  • Otani, Saria
  • Molenkamp, Richard
  • Nieuwenhuijse, David F.
  • Mbiribindi, Justin Bengehya
  • Belesi Siangoli, Freddy
  • Koopmans, Marion
  • Aarestrup, Frank M.
  • Oude Munnink, Bas B.
Mpox virus consensus sequences have been deposited on GISAID under the accession IDs: EPI_ISL_19689371-19689381, EPI_ISL_19689399, EPI_ISL_19689575, EPI_ISL_19689632, and EPI_ISL_19689707.-- et al., Mpox is an emerging zoonotic disease that caused two public health emergencies of international concern within two years. Less is known about the interplay of microbial organisms in mpox lesions which could result in superinfections that exacerbate outcomes or delay recovery. We utilized a unified metagenomic sequencing approach involving slow-speed centrifugation and differential lysis on 19 mpox lesion swabs of hospitalized patients in South Kivu province (eastern DRC) to characterize bacteria, antimicrobial resistance genes, mpox virus (MPXV), and viral co-infections. High-quality MPXV whole-genome sequences were obtained until a Ct value of 27. Furthermore, co-infections with other clinically relevant viruses, such as varicella zoster virus and herpes simplex virus-2, were detected and confirmed by real-time PCR. In addition, metagenomic sequence analysis of the bacterial content showed the presence of bacteria associated with skin and soft tissue infection in 10 of the 19 samples analyzed. These bacteria had a high abundance of resistance genes, with possible implications for antimicrobial treatment based on the predicted antimicrobial resistance. In conclusion, we report the presence of bacterial and viral pathogens in mpox lesions and detection of widespread resistance genes to the standard antibiotic treatment. The possibility of a co-infection, including antimicrobial resistance, should be considered when discussing treatment options, along with the determination of the case-fatality ratio., [Importance] The mpox virus clade Ib lineage emerged in the eastern Democratic Republic of the Congo owing to continuous human-to-human transmission in a vulnerable patient population. A major challenge of this ongoing outbreak is its occurrence in regions with severely limited healthcare infrastructure. As a result, less is known about co-infections in affected patients. Identifying and characterizing pathogens, including their antimicrobial resistance, is crucial for reducing infection-related complications and improving antimicrobial stewardship. In this study, we applied a unified metagenomics approach to detect and characterize bacterial and viral co-infections in mpox lesions of hospitalized mpox patients in the eastern DRC., This study is part of the EDCTP3 programme (grant number 101195116 JUA KIVU and grant number 101103059 GREAT-LIFE) supported by the European Union. LMM, PN and JCU received support by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO) under the MRC-UKRI grant MC_PC_24001, which was awarded to local investigators and Kamituga Hospital for mpox disease characterisation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serological evidence of clade Ib Mpox transmission by sex workers and within household in South Kivu, DRC

  • Masirika, Leandre Murhula
  • Ndishimye, Pacifique
  • Udahemuka, Jean Claude
  • Otani, Saria
  • Aarestrup, Frank M.
  • Schuele, Leonard
  • Musabyimana, Jean Pierre
  • Mbiribindi, Justin Bengehya
  • Oude Munnink, Bas B.
  • Belesi Siangoli, Freddy
  • Koopmans, Marion
  • Vries, Rory D. de
Data availability: The data generated in this study are provided in the Source Data file. Patient-related data may be subject to patient confidentiality, or unavailable due to the use of pseudonymized data. This study used unique materials, which were custom-made for specific analyses (ELISA antigens and virus stocks). Materials are available upon request, will be released via a material transfer agreement and can otherwise be obtained via the included experimental protocols in the Methods. The consensus sequence of the clade Ib MPXV isolate is available on GISAID under the accession number EPI_ISL_19621388. MPXV clade Ib sequences used for phylogenetic analysis are available on GISAID under the accession numbers EPI_ISL_13056256, EPI_ISL_13056257, EPI_ISL_13056263, EPI_ISL_13056270, EPI_ISL_13056430, EPI_ISL_18886301, EPI_ISL_18886639, EPI_ISL_19004044, EPI_ISL_19004045, EPI_ISL_19004046, EPI_ISL_19079342, EPI_ISL_19079343, EPI_ISL_19079344, EPI_ISL_19093791, EPI_ISL_19093796, EPI_ISL_19093803, EPI_ISL_19093808, EPI_ISL_19093809, EPI_ISL_19093810, EPI_ISL_19093811, EPI_ISL_19093812, EPI_ISL_19093815, EPI_ISL_19093817, EPI_ISL_19093827, EPI_ISL_19093830, EPI_ISL_19093831, EPI_ISL_19093833, EPI_ISL_19093835, EPI_ISL_19305614, EPI_ISL_19305615, EPI_ISL_19345026, EPI_ISL_19345027, EPI_ISL_19345028, EPI_ISL_19345031, EPI_ISL_19345032, EPI_ISL_19345034, EPI_ISL_19348512, EPI_ISL_19350788, EPI_ISL_19357654, EPI_ISL_19361896, EPI_ISL_19363686, EPI_ISL_19364035, EPI_ISL_19364369, EPI_ISL_19364511, EPI_ISL_19364948, EPI_ISL_19365441, EPI_ISL_19365466, EPI_ISL_19365506, EPI_ISL_19365507, EPI_ISL_19365542, EPI_ISL_19365544, EPI_ISL_19366314, EPI_ISL_19366744, EPI_ISL_19367803, EPI_ISL_19381268, EPI_ISL_19382151, EPI_ISL_19382354, EPI_ISL_19382807, EPI_ISL_19382808, EPI_ISL_19382942, EPI_ISL_19382949, EPI_ISL_19382965, EPI_ISL_19388839, EPI_ISL_19417681, EPI_ISL_19422968, EPI_ISL_19422969, EPI_ISL_19424850, EPI_ISL_19429465, EPI_ISL_19431760, EPI_ISL_19431763, EPI_ISL_19434063, EPI_ISL_19439694, EPI_ISL_19439695, EPI_ISL_19439696, EPI_ISL_19440397, EPI_ISL_19456777, EPI_ISL_19460816, EPI_ISL_19460883, EPI_ISL_19460954, EPI_ISL_19462380, EPI_ISL_19462381, EPI_ISL_19484958, EPI_ISL_19502023, EPI_ISL_19502043, EPI_ISL_19502052, EPI_ISL_19502130, EPI_ISL_19502532, EPI_ISL_19557976, EPI_ISL_19586581, EPI_ISL_19587230, EPI_ISL_19587231, EPI_ISL_19587232, EPI_ISL_19587233, EPI_ISL_19587234, EPI_ISL_19587235, EPI_ISL_19587236, EPI_ISL_19587237, EPI_ISL_19587238, EPI_ISL_19587239, EPI_ISL_19587240, EPI_ISL_19587241, EPI_ISL_19587242, EPI_ISL_19587243, EPI_ISL_19587244, EPI_ISL_19587245, EPI_ISL_19587246, EPI_ISL_19587247, EPI_ISL_19587248, EPI_ISL_19587249, EPI_ISL_19587250, EPI_ISL_19587251, EPI_ISL_19587252, EPI_ISL_19587253, EPI_ISL_19587254, EPI_ISL_19587255, EPI_ISL_19587256, EPI_ISL_19587257, EPI_ISL_19587258, EPI_ISL_19587259, EPI_ISL_19587260, EPI_ISL_19587261, EPI_ISL_19587262, EPI_ISL_19587263, EPI_ISL_19587264, EPI_ISL_19587265, EPI_ISL_19599242, EPI_ISL_19599243, EPI_ISL_19599250, EPI_ISL_19599257, EPI_ISL_19602362, EPI_ISL_19602363, EPI_ISL_19602364, EPI_ISL_19602365, EPI_ISL_19602366, EPI_ISL_19602367, EPI_ISL_19602368, EPI_ISL_19602369, EPI_ISL_19602370, EPI_ISL_19602371, EPI_ISL_19602372, EPI_ISL_19602373, EPI_ISL_19602374, EPI_ISL_19602375, EPI_ISL_19602376, EPI_ISL_19602377, EPI_ISL_19602378, EPI_ISL_19602379, EPI_ISL_19602380, EPI_ISL_19602381, EPI_ISL_19602382, EPI_ISL_19602383, EPI_ISL_19602384, EPI_ISL_19612225, EPI_ISL_19612226, EPI_ISL_19612227, EPI_ISL_19612228, EPI_ISL_19612229, EPI_ISL_19612230, EPI_ISL_19612231, EPI_ISL_19612232, EPI_ISL_19612233, EPI_ISL_19612234, EPI_ISL_19612235, EPI_ISL_19612236, EPI_ISL_19612237.-- et al., Understanding secondary attack rates is a key knowledge gap in the ongoing clade Ib mpox virus (MPXV) outbreak in the Democratic Republic of the Congo. Here, we report the first cross-sectional serological study to investigate local MPXV clade Ib transmission in South Kivu, DRC. Seropositivity was defined as a detectable titer in a cell lysate-based screening ELISA and confirmation by virus neutralization test. Sera were collected in November and December 2023 (n = 120), and in May 2024 (n = 48) from professional sex workers (PSW) and visitors of 25 bars with reports of mpox cases. We detected serological evidence for MPXV infection in 18% and 17% of these sera, respectively, indicating that PSW played an important role in MPXV clade Ib transmission in this region. Additionally, sera from 108 direct contacts of mpox cases from 34 households were collected between September 2023 and May 2024. Serological evidence for MPXV infection was found in at least one serum sample in 50% of households, including in nine households with seropositive minors, providing evidence for close-contact household transmission. Serological studies are needed to comprehend the extent and severity of the ongoing MPXV outbreak, and may be used to guide targeted vaccination strategies, particularly for high-risk groups., This study received partial funding from the EDCTP-funded projects GREAT-LIFE (grant numbers 101103059, laboratory training; awarded to FMA and MPGK) and JUA KIVU (grant number 101195116, study design and execution; awarded to MPGK, FMA, BBOM, RDDV, LMM, JCU, and PN). Assay development at Erasmus MC was supported through the HERA project DURABLE (grant number 101102733; awarded to MPGK) and the Netherlands Organization for Health Research and Development (ZonMw, grant agreement 10150022310035; awarded to LMZ and RDDV). We gratefully acknowledge the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO) for their research support under the MRC-UKRI grant MC_PC_24001, which was awarded to local investigators, Kamituga Hospital, and the Division Provinciale de la Santé (DPS, Provincial Division of Health) in South Kivu, Bukavu. We also acknowledge the Wildlife Conservation Network (WCN) and Conservation Action Research Network (CARN) for the scholarship and research support they awarded to LMM. We would like to thank the DPS of South Kivu and Kamituga Health Zone for their collaboration during the study. Finally, the DPS acknowledges the support of the Bill & Melinda Gates Foundation [INV-078955 AIMS-NEI]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The following people from the GREAT-LIFE mpox group provided technical assistance to the study: Nadine Bubala Malyamungu, Felix Camarade Habarugira, Francisco Bacon Benimana, Chantal Umubyeyi and Leandre Mutimbwa Mambo. We acknowledge Martin E. van Royen (Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands) for technical expertise regarding imaging, Eric van Gorp (Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands) for the collection of validation sera in the COVA study, and Sandra Scherbeijn (Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands) for performing HIV serology. Finally, we greatly thank Christian Gortázar (SaBio Instituto de Investigación en Recursos Cinegéticos, Universidad de Castilla-La Mancha y CSIC, Ciudad Real, Spain) and Trudie Lang (The Global Health Network (TGHN), University of Oxford, Oxford, United Kingdom) for their advice., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Capacity building for genomic surveillance of mpox and other emerging diseases in resource-limited settings within the African Great Lakes region

  • Schuele, Leonard
  • Udahemuka, Jean Claude
  • Masirika, Leandre Murhula
  • Nieuwenhuijse, David F.
  • Molenkamp, Richard
  • Boter, Marjan
  • Musabyimana, Jean Pierre
  • Vries, Rory D. de
  • Mbiribindi, Justin Bengehya
  • Belesi Siangoli, Freddy
  • Otani, Saria
  • Aarestrup, Frank M.
  • Koopmans, Marion
  • Ndishimye, Pacifique
  • Oude Munnink, Bas B.
Schuele, Leonard; et al., Genomic surveillance has become an indispensable tool for the identification of pathogens and tracking of transmission chains. Building upon the global sequencing and surveillance infrastructure developed and expanded during the COVID-19 pandemic, these capacities are now being adapted to track other pathogens in low- and middle-income countries which remain disproportionately affected by infectious diseases. This is evident in the recent and unprecedented spread of mpox virus in regions experiencing multiple concurrent infectious disease outbreaks, highlighting the need for broad, adaptable diagnostic detection and sequencing capacity. In this Perspective, we describe the applications, insights, and challenges encountered during ongoing capacity building efforts for the characterization of the mpox outbreak and other emerging pathogens in the African Great Lakes Region., This work is part of the EDCTP3 programme (grant number 101195116 JUA KIVU and grant number 101103059 GREAT-LIFE)., Peer reviewed